Andy Leaver, Partner & Chairman
Andy has a strong track record of building and developing pharmaceutical businesses. Andy founded pharmaceuticals company Clinigen in 2010 which floated on the AIM market in September 2012 and was hailed as one of the best stock market launches of the year. Starting out as a supplier of medicines for clinical trials, the company quickly developed into a global provider of specialist pharmaceutical products and services. This success provides valuable experience and insights for growing businesses, particularly in product development, acquisitions and international expansion.
Andrew Borkowski, Partner & CEO
Prior to co-founding Fullbrook Thorpe Investments, Andrew was a partner at Geldards LLP, a national commercial law firm. Andrew has over 25 years’ experience in corporate finance, specialising in mergers, acquisitions, fundraising and IPOs. Andrew also has non-executive roles with a number of companies.
Tom Leaver, Partner & Commercial Director
Tom has a strong pharmaceutical background having worked at Clinigen prior to its float. He brings youth and vitality to FTI and has a keen interest in disruptive technology and emerging pharmaceutical markets, always keen to seek out new opportunities.
Lucy Thomas, Finance Director
Lucy has worked with Andy in the pharmaceutical industry for over 15 years and is a qualified chartered accountant. Overseeing the accounting and financial control functions of FTI and ensuring compliance with all regulatory matters, Lucy is pivotal to the smooth operation of the business.
Debbie White, Executive PA
Debbie provides crucial support to ensure the operational effectiveness of our team. With extensive experience gained in corporate legal and finance environments, Debbie ensures that every aspect of our business is founded on best practice.